Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Consulting agrmnt
Director departure
Appointed director
CC transcript
Notes underwriting agrmnt
Inv. presentation
|
|
Sarepta Therapeutics, Inc. (SRPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/28/2021 |
GN
| Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021 |
| 03/18/2021 |
GN
| Sarepta Therapeutics' Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration |
| 03/15/2021 |
GN
| Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference |
| 03/01/2021 |
GN
| Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments |
| 02/26/2021 |
GN
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 02/25/2021 |
GN
| Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 |
| 02/24/2021 |
GN
| Sarepta Therapeutics to Present at Upcoming Investor Conferences |
| 02/22/2021 |
GN
| Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021 |
| 02/04/2021 |
GN
| Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition |
| 01/29/2021 |
GN
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 01/13/2021 |
GN
| Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics |
| 01/12/2021 |
GN
| Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm |
| 01/12/2021 |
GN
| SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of SRPT, PS, RP, and PGZ; Shareholders are Encouraged to Contact the Firm |
| 01/07/2021 |
GN
| Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy |
| 12/31/2020 |
GN
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12/14/2020 |
GN
| Sarepta Therapeutics Announces Executive Management Changes |
| 11/30/2020 |
GN
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 11/25/2020 |
GN
| Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference |
| 11/20/2020 |
GN
| Sarepta Therapeutics Named One of The Boston Globe's Top Places to Work 2020 |
| 11/02/2020 |
GN
| Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference |
| 10/30/2020 |
GN
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 10/22/2020 |
GN
| Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics |
| 09/30/2020 |
GN
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 09/28/2020 |
GN
| Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration |
| 09/28/2020 |
GN
| Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy |
| 09/14/2020 |
GN
| Long-term functional data from Sarepta Therapeutics' Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society |
| 09/03/2020 |
GN
| Sarepta Therapeutics to Present at Upcoming Investor Conferences |
| 08/31/2020 |
GN
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08/25/2020 |
GN
| Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45 |
| 07/31/2020 |
GN
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07/29/2020 |
GN
| Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020 |
| 07/24/2020 |
GN
| Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy |
| 07/15/2020 |
GN
| Sarepta Therapeutics Launches “Rare Lessons” Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare Diseases |
| 07/02/2020 |
GN
| Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase |
|
|
|